Positron (OTCMKTS:POSC – Get Free Report) is one of 74 publicly-traded companies in the “Electromedical equipment” industry, but how does it compare to its peers? We will compare Positron to related businesses based on the strength of its dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.
Institutional & Insider Ownership
44.1% of shares of all “Electromedical equipment” companies are held by institutional investors. 17.2% of Positron shares are held by company insiders. Comparatively, 15.0% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk and Volatility
Positron has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Positron’s peers have a beta of 17.00, meaning that their average stock price is 1,600% more volatile than the S&P 500.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Positron | -300.00% | N/A | -89.57% |
Positron Competitors | -331.31% | -92.24% | -30.04% |
Valuation and Earnings
This table compares Positron and its peers gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Positron | $740,000.00 | -$1.64 million | -12.00 |
Positron Competitors | $1.00 billion | $85.30 million | 5.74 |
Positron’s peers have higher revenue and earnings than Positron. Positron is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Analyst Ratings
This is a breakdown of recent ratings for Positron and its peers, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Positron | 0 | 0 | 0 | 0 | N/A |
Positron Competitors | 270 | 802 | 2016 | 109 | 2.61 |
As a group, “Electromedical equipment” companies have a potential upside of 3,305.07%. Given Positron’s peers higher probable upside, analysts plainly believe Positron has less favorable growth aspects than its peers.
Summary
Positron peers beat Positron on 7 of the 10 factors compared.
About Positron
Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.
Receive News & Ratings for Positron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Positron and related companies with MarketBeat.com's FREE daily email newsletter.